 SAN DIEGO, Nov. 16, 2020 GLOBE NEWSWIRE -- Exagen Inc. Nasdaq: XGN, an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc GSK, one of the worlds leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus SLE, the most common and severe form of lupus. At the center of the program are the proprietary AVISE laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential. 